Dear Editor: I am writing to express my concerns and disappointment about Dr. Norman Levine's editorial comments published in the March issue of Dermatology Times ("The elephant in our living room: What is happening to dermatology?"). As co-chairman of the section on communications for the American Academy of Dermatology, no one is more acutely aware of the changing trends in dermatology than I am. Each time we consider implementing a new communications program for the academy, we must consider the interest of the entire membership. This, of course, has become increasingly difficult over the years due to the fact that our specialty now encompasses medically, surgically, and cosmetically oriented dermatologists.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.